Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling

International Journal of Oncology

Volumn 45, Issue 2, 2014, Pages 795-803

  Liu, Yang ^a   Liu, Ying Zi ^a   Zhang, Ran Xi ^a   Wang, Xing ^a   Meng, Zi Jun ^a   Huang, Jun ^a   Wu, Ke ^a   Luo, Jin Yong ^a   Zuo, Guo Wei ^a   Chen, Liang ^a   Yin, Liang Jun ^a   Deng, Zhong Liang ^a   He, Bai Cheng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Dkk 1; Oridonin; Osteosarcoma; Proliferation inhibition; Wnt catenin signaling

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; DICKKOPF 1 PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; ORIDONIN; KAURANE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR XENOGRAFT; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; BONE TUMOR; DRUG EFFECTS; FLOW CYTOMETRY; METABOLISM; NUDE MOUSE; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DITERPENES, KAURANE; FEMALE; FLOW CYTOMETRY; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY;

EID: 84902594810     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2456     Document Type: Article

References (50)

1. Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32: 423-436, 2006. (Pubitemid 44309249)
2. Ando K, Heymann MF, Stresing V, Mori K, Redini F and Heymann D: Current therapeutic strategies and novel approaches in osteosarcoma. Cancers 5: 591-616, 2013.
3. Abelson PH: Medicine from plants. Science 247: 513, 1990.
4. Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S and Ikejima T: Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells. Biol Pharm Bull 29: 1873-1879, 2006. (Pubitemid 44338410)
5. Zhu Y, Xie L, Chen G, Wang H and Zhang R: Effects of oridonin on proliferation of HT29 human colon carcinoma cell lines both in vitro and in vivo in mice. Pharmazie 62: 439-444, 2007. (Pubitemid 46975266)
6. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 337: 224-231, 2005. (Pubitemid 41393783)
7. Zhou GB, Kang H, Wang L, et al: Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t (8;21) leukemia in vitro and in vivo. Blood 109: 3441-3450, 2007. (Pubitemid 46572534)
8. Jin S, Shen JN, Wang J, Huang G and Zhou JG: Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther 6: 261-268, 2007. (Pubitemid 46641633)
9. Behrens J and Lustig B: The Wnt connection to tumorigenesis. Int J Dev Biol 48: 477-487, 2004. (Pubitemid 39360398)
10. Barker N and Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5: 997-1014, 2006. (Pubitemid 44835127)
11. Lin YC, You L, Xu Z, et al: Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem Biophys Res Commun 341: 635-640, 2006. (Pubitemid 43152150)
12. Weeraratna AT, Jiang Y, Hostetter G, et al: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1: 279-288, 2002. (Pubitemid 41039152)
13. Wissmann C, Wild PJ, Kaiser S, et al: WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201: 204-212, 2003. (Pubitemid 37258931)
14. Hoang BH, Kubo T, Healey JH, et al: Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109: 106-111, 2004. (Pubitemid 38160669)
15. Iozzo RV, Eichstetter I and Danielson KG: Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res 55: 3495-3499, 1995.
16. Lu BJ, Wang YQ, Wei XJ, et al: Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma. Mol Med Rep 5: 1033-1036, 2012.
17. Ma Y, Ren Y, Han EQ, et al: Inhibition of the Wnt-beta-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun 431: 274-279, 2013.
18. Kansara M, Tsang M, Kodjabachian L, et al: Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119: 837-851, 2009.
19. Gao FH, Hu XH, Li W, et al: Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 10: 610, 2010.
20. He BC, Chen L, Zuo GW, et al: Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 16: 2235-2245, 2010.
21. Wu K, Yang Q, Mu Y, et al: Berberine inhibits the proliferation of colon cancer cells by inactivating Wnt/beta-catenin signaling. Int J Oncol 41: 292-298, 2012.
22. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998. (Pubitemid 28145972)
23. Tang N, Song WX, Luo J, et al: BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. J Cell Mol Med 13: 2448-2464, 2009.
24. He BC, Gao JL, Luo X, et al: Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/β-catenin signaling. Int J Oncol 38: 437-445, 2011.
25. Park HR and Park YK: Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone. J Korean Med Sci 10: 360-367, 1995.
26. Davidson G and Niehrs C: Emerging links between CDK cell cycle regulators and Wnt signaling. Trends Cell Biol 20: 453-460, 2010.
27. Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129: 199-221, 2003. (Pubitemid 36713796)
28. Nakamura T, Hamada F, Ishidate T, et al: Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level. Genes Cells 3: 395-403, 1998. (Pubitemid 28387083)
29. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995. (Pubitemid 26004411)
30. Bikkavilli RK, Feigin ME and Malbon CC: p38 mitogen-activated protein kinase regulates canonical Wnt-beta-catenin signaling by inactivation of GSK3beta. J Cell Sci 121: 3598-3607, 2008.
31. Li CY, Wang EQ, Cheng Y and Bao JK: Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int J Biochem Cell Biol 43: 701-704, 2011.
32. Zhang CL, Wu LJ, Zuo HJ, Tashiro S, Onodera S and Ikejima T: Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation. J Pharmacol Sci 96: 155-163, 2004. (Pubitemid 39469606)
33. Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S and Ikejima T: Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys 490: 70-75, 2009.
34. Hu HZ, Yang YB, Xu XD, et al: Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin 28: 1819-1826, 2007.
35. Li X, Li X, Wang J, Ye Z and Li JC: Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int J Biol Sci 8: 901-912, 2012.
36. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000.
37. Baron R and Kneissel M: WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19: 179-192, 2013.
38. Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature 434: 843-850, 2005. (Pubitemid 40558990)
39. Haydon RC, Deyrup A, Ishikawa A, et al: Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102: 338-342, 2002. (Pubitemid 35265873)
40. Rubin EM, Guo Y, Tu K, Xie J, Zi X and Hoang BH: Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther 9: 731-741, 2010.
41. Guo Y, Rubin EM, Xie J, Zi X and Hoang BH: Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res 466: 2039-2045, 2008.
42. Mishra R: Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 9: 144, 2010.
43. Wu J, Liao Q, He H, Zhong D and Yin K: TWIST interacts with beta-catenin signaling on osteosarcoma cell survival against cisplatin. Mol Carcinog: Dec 31, 2012(Epub ahead of print). doi: 10.1002/mc.21991.
44. Xia JJ, Pei LB, Zhuang JP, et al: Celecoxib inhibits beta-catenin- dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res 38: 1294-1304, 2010.
45. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G and Cleton-Jansen AM: Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 220: 24-33, 2010.
46. Tang QL, Xie XB, Wang J, et al: Glycogen synthase kinase-3beta, NF-kappaB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst 104: 749-763, 2012.
47. Zorn AM: Wnt signalling: antagonistic Dickkopfs. Curr Biol 11: R592-R595, 2001.
48. Kawano Y and Kypta R: Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116: 2627-2634, 2003. (Pubitemid 36857216)
49. Lin CH, Guo Y, Ghaffar S, et al: Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma 2013: 147541, 2013.
50. Hoang BH, Kubo T, Healey JH, et al: Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 64: 2734-2739, 2004. (Pubitemid 38500609)